• Title: Rodman & Renshaw / Life Sciences: NAASO '08 Wrap Up
• Artist: Zangani Investor Community(TM)
• Genre: Other
• Length: 47:11 minutes (10.8 MB)
• Format: Mono 22kHz 32Kbps (CBR)

Rodman & Renshaw LLC and and MedKnowledge present the latest in a series of medical expert conference calls. Michael G. King, Jr., Senior Biotechnology Analyst, hosts the call featuring:

Ken Fujioka, MD - Director, Nutrition & Metabolic Research Center, Scripps Clinic - Del Mar, San Diego

Dr. Ken Fujioka is Director of the Nutrition and Metabolic Research Center and a member of the Division of Diabetes and Endocrinology at the Scripps Clinic - Del Mar in San Diego, California. Dr. Fujioka has authored or co-authored more than 50 scientific papers and abstracts and he has completed more than 75 clinical trials in the field of obesity and other related diseases including diabetes, hypercholesterolemia, and hypertension. In 1997, he authored a comprehensive analysis of the appropriate treatment of the obese patient for the state of California, and he served as an expert witness for the Medical Board of California on the appropriate use of weight loss agents in the treatment of the obese patient. Dr. Fujioka also has addressed the Joint Steering Committee for Public Policy on Capitol Hill regarding obesity and nutritional supplements. Currently, he is a reviewer for The Journal of the American Medical Association (JAMA), Obesity Research, Diabetes Care, Obstetrics and Gynecology, and Diabetes, Obesity and Metabolism.

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM) is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC, Rodman Principal Investments, LLC, and Miller Mathis & Co. Rodman & Renshaw, LLC is a full service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies, along with research, sales and trading services to investor clients that focus on such companies. Rodman is a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transactions markets.